Compare Stocks: STTK, NRIX, SLS, and VRDN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NRIX Nurix Therapeutics	$25.35 -1.8%	$24.79	$8.19 ▼ $28.23	$2.63B	1.8	1.45 million shs	92,410 shs
SLS SELLAS Life Sciences Group	$14.16 0.0%	$12.75	$1.39 ▼ $15.88	$2.86B	2.52	8.20 million shs	1.27 million shs
STTK Shattuck Labs	$6.98 +1.1%	$7.13	$1.19 ▼ $8.33	$703.32M	1.09	885,670 shs	50,594 shs
VRDN Viridian Therapeutics	$22.73 -0.2%	$20.90	$13.18 ▼ $34.29	$2.57B	0.97	2.12 million shs	86,907 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NRIX Nurix Therapeutics	-0.84%	-3.33%	+11.20%	+68.98%	+183.42%
SLS SELLAS Life Sciences Group	+7.11%	+3.13%	+26.20%	+56.64%	+673.77%
STTK Shattuck Labs	+0.58%	-12.53%	-5.21%	+43.96%	+584.16%
VRDN Viridian Therapeutics	-1.09%	-6.10%	+17.97%	+37.48%	+19.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NRIX Nurix Therapeutics	$25.35 -1.8%	$24.79	$8.19 ▼ $28.23	$2.63B	1.8	1.45 million shs	92,410 shs
SLS SELLAS Life Sciences Group	$14.16 0.0%	$12.75	$1.39 ▼ $15.88	$2.86B	2.52	8.20 million shs	1.27 million shs
STTK Shattuck Labs	$6.98 +1.1%	$7.13	$1.19 ▼ $8.33	$703.32M	1.09	885,670 shs	50,594 shs
VRDN Viridian Therapeutics	$22.73 -0.2%	$20.90	$13.18 ▼ $34.29	$2.57B	0.97	2.12 million shs	86,907 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NRIX Nurix Therapeutics	-0.84%	-3.33%	+11.20%	+68.98%	+183.42%
SLS SELLAS Life Sciences Group	+7.11%	+3.13%	+26.20%	+56.64%	+673.77%
STTK Shattuck Labs	+0.58%	-12.53%	-5.21%	+43.96%	+584.16%
VRDN Viridian Therapeutics	-1.09%	-6.10%	+17.97%	+37.48%	+19.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NRIX Nurix Therapeutics	2.80	Moderate Buy	$34.21	34.95% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-29.35% Downside
STTK Shattuck Labs	3.00	Buy	$12.78	82.98% Upside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.54	69.58% Upside

Current Analyst Ratings Breakdown

Latest STTK, NRIX, SLS, and VRDN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/12/2026	SLS SELLAS Life Sciences Group	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	STTK Shattuck Labs	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$18.00 ➝ $14.00
8/10/2026	NRIX Nurix Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$33.00 ➝ $36.00
8/7/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $36.00
8/7/2026	VRDN Viridian Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00
8/4/2026	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
7/28/2026	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$36.00 ➝ $38.00
7/24/2026	STTK Shattuck Labs	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NRIX Nurix Therapeutics	$83.98M	31.33	N/A	N/A	$5.29 per share	4.79
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.68 per share	N/A
STTK Shattuck Labs	$1M	700.81	N/A	N/A	$2.10 per share	3.33
VRDN Viridian Therapeutics	$70.85M	36.34	N/A	N/A	$4.98 per share	4.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NRIX Nurix Therapeutics	-$264.46M	-$3.45	N/A	N/A	N/A	-928.44%	-76.09%	-57.31%	10/8/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest STTK, NRIX, SLS, and VRDN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
7/9/2026	Q2 2026	NRIX Nurix Therapeutics	-$0.73	-$0.81	-$0.08	-$0.81	$15.29 million	$9.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NRIX Nurix Therapeutics	N/A	6.34	6.34
SLS SELLAS Life Sciences Group	N/A	18.83	18.83
STTK Shattuck Labs	N/A	27.59	27.59
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NRIX Nurix Therapeutics	N/A
SLS SELLAS Life Sciences Group	17.38%
STTK Shattuck Labs	58.74%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
NRIX Nurix Therapeutics	6.70%
SLS SELLAS Life Sciences Group	1.30%
STTK Shattuck Labs	8.79%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NRIX Nurix Therapeutics	300	103.78 million	96.83 million	Optionable
SLS SELLAS Life Sciences Group	10	201.95 million	199.32 million	Not Optionable
STTK Shattuck Labs	100	100.36 million	91.54 million	Optionable
VRDN Viridian Therapeutics	50	113.29 million	110.57 million	Optionable

STTK, NRIX, SLS, and VRDN Headlines

Recent News About These Companies

Velan Capital Investment Management LP Has $184,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

4 hours ago | marketbeat.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2 at 8:34 PM | finance.yahoo.com

The Manufacturers Life Insurance Company Takes $3.31 Million Position in Viridian Therapeutics, Inc. $VRDN

September 2 at 4:48 AM | marketbeat.com

Yiheng Capital Management L.P. Has $7.36 Million Holdings in Viridian Therapeutics, Inc. $VRDN

August 31 at 6:31 AM | marketbeat.com

Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN

August 27, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

Elmind Capital LP Purchases Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $25.31 Million Investment in Viridian Therapeutics, Inc. $VRDN

August 25, 2026 | marketbeat.com

Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN

August 24, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP

August 21, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares

August 20, 2026 | marketbeat.com

Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN

August 20, 2026 | marketbeat.com

GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN

August 19, 2026 | marketbeat.com

93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc.

August 18, 2026 | marketbeat.com

1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC

August 18, 2026 | marketbeat.com

Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN

August 18, 2026 | marketbeat.com

Viridian Therapeutics Inc VRDN

August 15, 2026 | morningstar.comM

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

HC Wainwright Has Negative Forecast for VRDN Q3 Earnings

August 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, NRIX, SLS, and VRDN Company Descriptions

Nurix Therapeutics NASDAQ:NRIX

$25.35 -0.47 (-1.81%)

As of 10:50 AM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

SELLAS Life Sciences Group NASDAQ:SLS

$14.16 -0.01 (-0.04%)

As of 10:50 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Shattuck Labs NASDAQ:STTK

$6.98 +0.07 (+1.06%)

As of 10:50 AM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Viridian Therapeutics NASDAQ:VRDN

$22.73 -0.05 (-0.24%)

As of 10:50 AM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, NRIX, SLS, and VRDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, NRIX, SLS, and VRDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, NRIX, SLS, and VRDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, NRIX, SLS, and VRDN Company Descriptions

Nurix Therapeutics NASDAQ:NRIX

SELLAS Life Sciences Group NASDAQ:SLS

Shattuck Labs NASDAQ:STTK

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, NRIX, SLS, and VRDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, NRIX, SLS, and VRDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, NRIX, SLS, and VRDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, NRIX, SLS, and VRDN Company Descriptions

Nurix Therapeutics NASDAQ:NRIX

SELLAS Life Sciences Group NASDAQ:SLS

Shattuck Labs NASDAQ:STTK

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools